Contact
searchSearch
HMP Global

Advertisement

Advertisement

Advertisement

ADVERTISEMENT

Ankylosing Spondylitis Topic Center

Featured Article

News
Opioid Use Associated With Fractures in People With Ankylosing Spondylitis
12/20/2023
Increasing age, historical fracture, and opioid use are associated with higher odds of fracture in ankylosing spondylitis (AS), according to a study published in Arthritis Care & Research. “We performed a retrospective cohort study...
Increasing age, historical fracture, and opioid use are associated with higher odds of fracture in ankylosing spondylitis (AS), according to a study published in Arthritis Care & Research. “We performed a retrospective cohort study...
Increasing age, historical...
12/20/2023
First Report Managed Care
News
Analysis Finds Similar Safety Profile with Upadacitinib Across Conditions
11/03/2023
The Janus kinase (JAK) inhibitor upadacitinib offers a similar long-term safety profile across rheumatoid arthritis (RA), psoriatic arthritis (PsA), ankylosing spondylitis (AS), and atopic dermatitis (AD) despite some variations in adverse...
The Janus kinase (JAK) inhibitor upadacitinib offers a similar long-term safety profile across rheumatoid arthritis (RA), psoriatic arthritis (PsA), ankylosing spondylitis (AS), and atopic dermatitis (AD) despite some variations in adverse...
The Janus kinase (JAK) inhibitor...
11/03/2023
First Report Managed Care
News
High Rates of Depression, Anxiety in Patients With Ankylosing Spondylitis
10/06/2023
Half of patients with ankylosing spondylitis had clinically significant depression, and more than a third had clinically significant anxiety, according to a single-center, cross-sectional study currently underway.
Half of patients with ankylosing spondylitis had clinically significant depression, and more than a third had clinically significant anxiety, according to a single-center, cross-sectional study currently underway.
Half of patients with ankylosing...
10/06/2023
First Report Managed Care
News
Achieving Disease Control in PsA, AS Associated with Lower Medical Costs
09/15/2023
A study published in Rheumatology and Therapy found that individuals diagnosed with psoriatic arthritis (PsA) or ankylosing spondylitis (AS) and exhibiting lower levels of disease activity incurred reduced healthcare resource utilization and...
A study published in Rheumatology and Therapy found that individuals diagnosed with psoriatic arthritis (PsA) or ankylosing spondylitis (AS) and exhibiting lower levels of disease activity incurred reduced healthcare resource utilization and...
A study published in...
09/15/2023
First Report Managed Care
News
Fear of Movement in Patients With Ankylosing Spondylitis Linked With Lower Life Quality
07/27/2023
Research findings indicate a link between kinesiophobia, a fear of movement and injury, and decreased quality of life in patients with ankylosing spondylitis.
Research findings indicate a link between kinesiophobia, a fear of movement and injury, and decreased quality of life in patients with ankylosing spondylitis.
Research findings indicate a...
07/27/2023
First Report Managed Care
News
Tildrakizumab No Better Than Placebo for Ankylosing Spondylitis
06/09/2023
A 48-week trial of tildrakizumab in patients with ankylosing spondylitis was terminated early after researchers found that the drug had no efficacy in comparison to placebo.
A 48-week trial of tildrakizumab in patients with ankylosing spondylitis was terminated early after researchers found that the drug had no efficacy in comparison to placebo.
A 48-week trial of tildrakizumab...
06/09/2023
First Report Managed Care
News
Risk of Psychiatric Comorbidity Higher in Patients With Ankylosing Spondylitis
05/19/2023
Findings from a population-based, cross-sectional study suggest that patients with ankylosing spondylitis are at a higher risk of developing psychiatric disorders.
Findings from a population-based, cross-sectional study suggest that patients with ankylosing spondylitis are at a higher risk of developing psychiatric disorders.
Findings from a...
05/19/2023
First Report Managed Care
News
Short-term Biosimilar Adalimumab Provides Long-term Relief for Ankylosing Spondylitis
04/14/2023
Treatment with biosimilar adalimumab was associated with a significant improvement in ankylosing spondylitis symptoms for up to 1 year, according to new findings.
Treatment with biosimilar adalimumab was associated with a significant improvement in ankylosing spondylitis symptoms for up to 1 year, according to new findings.
Treatment with biosimilar...
04/14/2023
First Report Managed Care
News
JAK Inhibitor Improves Slate of Patient-Reported Outcomes in Biologic Refractory Ankylosing Spondylitis
03/28/2023
Researchers studied a JAK inhibitor's efficacy for improving disease activity, health-related quality of life, and other measures in a cohort of patients with ankylosing spondylitis who did not respond or tolerate biologics.
Researchers studied a JAK inhibitor's efficacy for improving disease activity, health-related quality of life, and other measures in a cohort of patients with ankylosing spondylitis who did not respond or tolerate biologics.
Researchers studied a JAK...
03/28/2023
First Report Managed Care
News
Baseline Variables Predict Probability of Initial Response to TNFi Inhibitors in Patients With AS
10/27/2022
Researchers sought to develop models of the probability of short-term response to tumor necrosis factor inhibitor treatment in patients with ankylosing spondylitis.
Researchers sought to develop models of the probability of short-term response to tumor necrosis factor inhibitor treatment in patients with ankylosing spondylitis.
Researchers sought to develop...
10/27/2022
First Report Managed Care
News
Categorizing Disease Activity in Ankylosing Spondylitis: SASDAS vs ASDAS
09/09/2022
Researchers compared the Ankylosing Spondylitis Disease Activity Score to a simplified version of the tool to categorize patients’ disease.
Researchers compared the Ankylosing Spondylitis Disease Activity Score to a simplified version of the tool to categorize patients’ disease.
Researchers compared the...
09/09/2022
First Report Managed Care

Newsfeed

News
Opioid Use Associated With Fractures in People With Ankylosing Spondylitis
12/20/2023
Increasing age, historical fracture, and opioid use are associated with higher odds of fracture in ankylosing spondylitis (AS), according to a study published in Arthritis Care & Research. “We performed a retrospective cohort study...
Increasing age, historical fracture, and opioid use are associated with higher odds of fracture in ankylosing spondylitis (AS), according to a study published in Arthritis Care & Research. “We performed a retrospective cohort study...
Increasing age, historical...
12/20/2023
First Report Managed Care
News
Analysis Finds Similar Safety Profile with Upadacitinib Across Conditions
11/03/2023
The Janus kinase (JAK) inhibitor upadacitinib offers a similar long-term safety profile across rheumatoid arthritis (RA), psoriatic arthritis (PsA), ankylosing spondylitis (AS), and atopic dermatitis (AD) despite some variations in adverse...
The Janus kinase (JAK) inhibitor upadacitinib offers a similar long-term safety profile across rheumatoid arthritis (RA), psoriatic arthritis (PsA), ankylosing spondylitis (AS), and atopic dermatitis (AD) despite some variations in adverse...
The Janus kinase (JAK) inhibitor...
11/03/2023
First Report Managed Care
News
High Rates of Depression, Anxiety in Patients With Ankylosing Spondylitis
10/06/2023
Half of patients with ankylosing spondylitis had clinically significant depression, and more than a third had clinically significant anxiety, according to a single-center, cross-sectional study currently underway.
Half of patients with ankylosing spondylitis had clinically significant depression, and more than a third had clinically significant anxiety, according to a single-center, cross-sectional study currently underway.
Half of patients with ankylosing...
10/06/2023
First Report Managed Care
News
Achieving Disease Control in PsA, AS Associated with Lower Medical Costs
09/15/2023
A study published in Rheumatology and Therapy found that individuals diagnosed with psoriatic arthritis (PsA) or ankylosing spondylitis (AS) and exhibiting lower levels of disease activity incurred reduced healthcare resource utilization and...
A study published in Rheumatology and Therapy found that individuals diagnosed with psoriatic arthritis (PsA) or ankylosing spondylitis (AS) and exhibiting lower levels of disease activity incurred reduced healthcare resource utilization and...
A study published in...
09/15/2023
First Report Managed Care
News
Fear of Movement in Patients With Ankylosing Spondylitis Linked With Lower Life Quality
07/27/2023
Research findings indicate a link between kinesiophobia, a fear of movement and injury, and decreased quality of life in patients with ankylosing spondylitis.
Research findings indicate a link between kinesiophobia, a fear of movement and injury, and decreased quality of life in patients with ankylosing spondylitis.
Research findings indicate a...
07/27/2023
First Report Managed Care
News
Tildrakizumab No Better Than Placebo for Ankylosing Spondylitis
06/09/2023
A 48-week trial of tildrakizumab in patients with ankylosing spondylitis was terminated early after researchers found that the drug had no efficacy in comparison to placebo.
A 48-week trial of tildrakizumab in patients with ankylosing spondylitis was terminated early after researchers found that the drug had no efficacy in comparison to placebo.
A 48-week trial of tildrakizumab...
06/09/2023
First Report Managed Care
News
Risk of Psychiatric Comorbidity Higher in Patients With Ankylosing Spondylitis
05/19/2023
Findings from a population-based, cross-sectional study suggest that patients with ankylosing spondylitis are at a higher risk of developing psychiatric disorders.
Findings from a population-based, cross-sectional study suggest that patients with ankylosing spondylitis are at a higher risk of developing psychiatric disorders.
Findings from a...
05/19/2023
First Report Managed Care
News
Short-term Biosimilar Adalimumab Provides Long-term Relief for Ankylosing Spondylitis
04/14/2023
Treatment with biosimilar adalimumab was associated with a significant improvement in ankylosing spondylitis symptoms for up to 1 year, according to new findings.
Treatment with biosimilar adalimumab was associated with a significant improvement in ankylosing spondylitis symptoms for up to 1 year, according to new findings.
Treatment with biosimilar...
04/14/2023
First Report Managed Care
News
JAK Inhibitor Improves Slate of Patient-Reported Outcomes in Biologic Refractory Ankylosing Spondylitis
03/28/2023
Researchers studied a JAK inhibitor's efficacy for improving disease activity, health-related quality of life, and other measures in a cohort of patients with ankylosing spondylitis who did not respond or tolerate biologics.
Researchers studied a JAK inhibitor's efficacy for improving disease activity, health-related quality of life, and other measures in a cohort of patients with ankylosing spondylitis who did not respond or tolerate biologics.
Researchers studied a JAK...
03/28/2023
First Report Managed Care
News
Baseline Variables Predict Probability of Initial Response to TNFi Inhibitors in Patients With AS
10/27/2022
Researchers sought to develop models of the probability of short-term response to tumor necrosis factor inhibitor treatment in patients with ankylosing spondylitis.
Researchers sought to develop models of the probability of short-term response to tumor necrosis factor inhibitor treatment in patients with ankylosing spondylitis.
Researchers sought to develop...
10/27/2022
First Report Managed Care
News
Using Deep Learning to Measure MS-Specific Brain Damage Beyond Aging
11/11/2024
A new study published in Neurology aimed to differentiate age-related brain changes from multiple sclerosis (MS)-specific neurodegeneration using MRI.
A new study published in Neurology aimed to differentiate age-related brain changes from multiple sclerosis (MS)-specific neurodegeneration using MRI.
A new study published in...
11/11/2024
First Report Managed Care
News
Adverse Event Data Suggest Selective β1-blockers Pose Asthma Risk
11/11/2024
The risks of asthma and asthma-like adverse events appear to be higher with selective β1-blockers than with nonselective blockers and α- and β-blockers.
The risks of asthma and asthma-like adverse events appear to be higher with selective β1-blockers than with nonselective blockers and α- and β-blockers.
The risks of asthma and...
11/11/2024
First Report Managed Care
News
RNAi Therapies Offer New Hope for Patients With Hereditary Transthyretin Amyloidosis
11/08/2024
RNA interference (RNAi)-based treatments for hereditary transthyretin amyloidosis (ATTR) have shown remarkable promise, offering new hope for patients with this rare but devastating genetic disorder.
RNA interference (RNAi)-based treatments for hereditary transthyretin amyloidosis (ATTR) have shown remarkable promise, offering new hope for patients with this rare but devastating genetic disorder.
RNA interference (RNAi)-based...
11/08/2024
First Report Managed Care
News
Revolutionary Single-Dose Gene Therapy Offers New Hope for Adults with Hemophilia B
11/08/2024
A groundbreaking gene therapy for hemophilia B has shown remarkable success in reducing bleeding episodes and improving the quality of life for adult patients, according to a recent international phase III clinical trial.
A groundbreaking gene therapy for hemophilia B has shown remarkable success in reducing bleeding episodes and improving the quality of life for adult patients, according to a recent international phase III clinical trial.
A groundbreaking gene therapy...
11/08/2024
First Report Managed Care
News
Real-World Evidence Supports Efficacy and Safety of Selexipag in Patients With Pulmonary Arterial Hypertension
11/07/2024
Real-world data shows selexipag effectively improves functional class and risk category outcomes in patients with pulmonary arterial hypertension, regardless of maintenance dose.
Real-world data shows selexipag effectively improves functional class and risk category outcomes in patients with pulmonary arterial hypertension, regardless of maintenance dose.
Real-world data shows selexipag...
11/07/2024
First Report Managed Care
News
Clinical Predictors of One-Year Seizure Freedom After SLAH
11/06/2024
A study published in Annals of Clinical and Translational Neurology aimed to predict 1-year seizure freedom for patients undergoing stereotactic laser amygdalohippocampotomy (SLAH) for mesial temporal lobe epilepsy (MTLE) using a set of...
A study published in Annals of Clinical and Translational Neurology aimed to predict 1-year seizure freedom for patients undergoing stereotactic laser amygdalohippocampotomy (SLAH) for mesial temporal lobe epilepsy (MTLE) using a set of...
A study published in Annals of...
11/06/2024
First Report Managed Care
News
Efficacy and Outcomes of Neoadjuvant Immunotherapy in Lung Cancer
11/05/2024
A meta-analysis of 43 studies suggests that neoadjuvant chemoimmunotherapy may benefit patients with resectable NSCLC and low tumor PD-L1 levels for event-free survival, showing superior outcomes compared to neoadjuvant chemotherapy.
A meta-analysis of 43 studies suggests that neoadjuvant chemoimmunotherapy may benefit patients with resectable NSCLC and low tumor PD-L1 levels for event-free survival, showing superior outcomes compared to neoadjuvant chemotherapy.
A meta-analysis of 43 studies...
11/05/2024
First Report Managed Care
News
FDA Grants Accelerated Approval for Asciminib as First-Line Treatment in Ph+CML-CP
11/01/2024
Novartis received accelerated approval by the US Food and Drug Administration (FDA) for asciminib, a medication for adult patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase (Ph+CML-CP).
Novartis received accelerated approval by the US Food and Drug Administration (FDA) for asciminib, a medication for adult patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase (Ph+CML-CP).
Novartis received accelerated...
11/01/2024
First Report Managed Care
News
HHS Faces Legal Action From 10 Hospitals Over 2023 Medicare Advantage Rule and Reimbursement Calculations
10/30/2024
Ten hospitals sued the US Department of Health and Human Services (HHS), claiming that they were underpaid Medicare reimbursements for serving low-income patients.
Ten hospitals sued the US Department of Health and Human Services (HHS), claiming that they were underpaid Medicare reimbursements for serving low-income patients.
Ten hospitals sued the US...
10/30/2024
First Report Managed Care
News
Impact of Immune Checkpoint Inhibitors on Multiple Sclerosis Treatment Outcomes
10/29/2024
Relapses and progression of multiple sclerosis were rare in patients treated with immune checkpoint inhibitors, according to a study presented at the American Academy of Neurology 2024 Annual Meeting.
Relapses and progression of multiple sclerosis were rare in patients treated with immune checkpoint inhibitors, according to a study presented at the American Academy of Neurology 2024 Annual Meeting.
Relapses and progression of...
10/29/2024
First Report Managed Care

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use

Advertisement

Advertisement